Research on Financial Risk Control of Cross-border M&A of Biopharmaceutical Enterprises: A Case Study of Sino Biopharma's Acquisition of F-star

Zilin Jin

doi:10.54254/2754-1169/2025.21993

Article Information

Received: 2 April 2025

Published: 10 April 2025

DOI: https://doi.org/10.54254/2754-1169/2025.21993

Article Type: Research Article

Cite this article

Jin,Z. (2025). Research on Financial Risk Control of Cross-border M&A of Biopharmaceutical Enterprises: A Case Study of Sino Biopharma's Acquisition of F-star. Advances in Economics, Management and Political Sciences,175,105-110.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: AEMPS Vol.175

Part of Series: Advances in Economics, Management and Political Sciences

ISSN: 2754-1169 (Print) / 2754-1177 (Online)

Copyright & License

[1]PWC. (2023) 2022 Global M&A Industry Trends Review and 2023 Outlook – Healthcare Industry. https://www.pwccn.com/zh/deals/global-ma-industry-trends-2023-outlook-hi.pdf

[2]Kwon, J. (2020). Moderating Effect of the Continental Factor on the Business Strategy and M&A Performance in the Pharmaceutical Industry for Sustainable International Business. Sustainability., 12(12). https://doi.org/10.3390/su12124985

[3]Business Wire. (2023) invoX Pharma Completes Acquisition of F-star Therapeutics, Inc. invoX Pharma Completes Acquisition of F-star Therapeutics, Inc. | Business Wire.

[4]Nasdaq. (2022) invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs. F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals | Nasdaq.

[5]F-star Therapeutics Inc. (2021) F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update. https://f-star.com/wp-content/uploads/2022/09/F-star-Therapeutics-Reports-Full-Year-2020-Financial-Results-and-Provides-Corporate-Update.pdf.

[6]Yahoo Finance. (2022) F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update. F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (yahoo.com).

[7]Global Health Council. (2022) Statement on the release of National Security Memorandum-15 and the National Biodefense Strategy. Statement on the release of National Security Memorandum-15 and the National Biodefense Strategy (globalhealth.org).

[8]The Paper, Government Affairs. (2023) The "first case" of Sino-US biomedicine lasted nine months and finally came to an end, and the potential for cooperation is still there. The "first case" of Sino-US biomedicine has finally come to an end after nine months, and the potential for cooperation is still there

[9]Zhu, G. (2020). Stock Price Volatility, Equity Balance and Corporate M&A. 2020 39th Chinese Control Conference (CCC) /, 7695–7699.

[10]Bei, W. (2018) Study on Financial Risk of Enterprise Merger and Acquisition. In: 10th International Conference on Financial Risk and Corporate Finance Management (FRCFM). Dalian. pp. 335–341.

[11]Appadu, N. (2016). Assessing market attractiveness for mergers and acquisitions: the M&A Attractiveness Index Score. The European Journal of Finance., 22(8–9), 732–755.

[12]Diduc, S. (2022). Integration team members’ approaches to uncertainty management in M&A. European Management Journal., 40(6), 917–931.